Companies 0 See All

Hedge Funds 0 See All

Insiders 0 See All

Institutional Investors 0 See All

Click here to see all results for

Home > Insider Trading > Filing (0000899243-22-001169)

Filing Details

Accession Number:: 0000899243-22-001169
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2022-01-06 16:06:27
Reporting Period:: 2022-01-04

Accepted Time:: 2022-01-06 16:06:27
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1743881	Bridgebio Pharma Inc.	BBIO	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1652908	A. Douglas Dachille	C/O Bridgebio Pharma, Inc. 421 Kipling Street Palo Alto CA 94301		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2022-01-04	5,000	$16.82	5,000	No	4	P	Indirect	By The Dachille 2012-1 Family Trust
Common Stock	Acquisiton	2022-01-05	5,000	$15.91	10,000	No	4	P	Indirect	By The Dachille 2012-1 Family Trust

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	By The Dachille 2012-1 Family Trust
No	4	P	Indirect	By The Dachille 2012-1 Family Trust

Footnotes

These shares are owned directly by The Dachille 2012-1 Family Trust for the benefit of the reporting person's children, for which the reporting person's spouse is the trustee. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.